Norditropin NordiFlex
Submitted by Anonymous (not verified) on 17 December 2024 - 13:43
Norditropin NordiFlex
Emer Cooke, EMA’s Executive Director: 2024 achievements in medicine regulation
Submitted by Anonymous (not verified) on 17 December 2024 - 13:34
Emer Cooke, EMA’s Executive Director: 2024 achievements in medicine regulation
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes
Submitted by Anonymous (not verified) on 17 December 2024 - 13:30
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes
European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal product applications: document with track changes
Submitted by Anonymous (not verified) on 17 December 2024 - 13:30
European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal product applications: document with track changes
European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal product applications
Submitted by Anonymous (not verified) on 17 December 2024 - 13:30
European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal product applications
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
Submitted by Anonymous (not verified) on 17 December 2024 - 13:30
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
Product Management Service (PMS) – Frequently Asked Questions (FAQs)
Submitted by Anonymous (not verified) on 17 December 2024 - 13:21
Product Management Service (PMS) – Frequently Asked Questions (FAQs)
Questions and answers on the consultation procedure to the European Medicines Agency by notified bodies on an ancillary medicinal substance or an ancillary human blood derivative incorporated in a medical device
Submitted by Anonymous (not verified) on 17 December 2024 - 13:20
Questions and answers on the consultation procedure to the European Medicines Agency by notified bodies on an ancillary medicinal substance or an ancillary human blood derivative incorporated in a medical device
European Medicines Agency procedural advice for users of the centralised procedure for generic / hybrid applications (track changes)
Submitted by Anonymous (not verified) on 17 December 2024 - 13:06
European Medicines Agency procedural advice for users of the centralised procedure for generic / hybrid applications (track changes)
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with track changes
Submitted by Anonymous (not verified) on 17 December 2024 - 13:06
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with track changes